Without the need for injection training or in-office administration, providers can shift their focus toward higher-value care activitiessuch as metabolic assessments, lifestyle counseling, progress tracking, and long-term outcome monitoring
In a statement, the Danish company said the move would help to address "access barriers" to the medicines and "make it easier and more affordable for people in the US to get authentic, FDA-approved Wegovy and Ozempic in the way that best fits their lives." There's little doubt that one of the reasons for the move will be to try to keep pace with arch-rival Eli Lilly in the market for incretin-based therapies for obesity and T2D, particularly the strong growth of Lilly's dual GIP/GLP-1 agonist tirzepatide, whose growth rate is outstripping Novo Nordisk's products
Pre-filled Injectable (commonly known as a "weight-loss pen" or "slimming pen") One subcutaneous injection per week, starting at a dose of 0.25 mg, gradually increased to a maintenance dose of 2.4 mg With one injection per week, the drug remains in the body for about 7 weeks
However, 2026 will be a turning point: as semaglutide loses patent protection in major global markets, such as China, Canada, and Brazil, and with liraglutide already off-patent in the US, the growth of generics is expected to drive down costs and improve global equity
